NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.92 USD
-1.30 (-8.54%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $13.94 +0.02 (0.14%) 6:48 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Brokerage Reports
0 items in cart
NeoGenomics, Inc. [NEO]
Reports for Purchase
Showing records 41 - 60 ( 132 total )
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
NeoGenomics reported solid financial results for their Q3/2015
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Nirvana as NEO finally Transcends The CMS
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Transformational Acquisition, Target to $10
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Preview - Upcoming CMS Update a Bigger Driver than 3Q Performance
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Premier Agreement Eliminates the Covance Overhang
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Q2/15 results strong; Rates could rebound
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Impact of Proposed Reimbursement Changes, Target to $7.50
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Christmas in July as CMS Comes to the Party
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Preview - Focus on Volume Growth and Impending Reimbursement
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.